Response of Paroxysmal Nocturnal Hemoglobinuria Clone with Aplastic Anemia to Rituximab

<table>The improvement in blood counts from the time of diagnosis to most recent. (a) white cell and neutrophil counts, (b) describes the hemoglobin trend, and (c) the platelet trend. The <svg height="7.1624999" id="M15" style="vertical-align:-0.11285pt" version="1.1" viewbox="0 0 8.7250004 7.1624999" width="8.7250004" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,7.1625)">
<g transform="translate(72,-66.27)">
<text transform="matrix(1,0,0,-1,-71.95,66.44)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑥</tspan>
</text>
</g>
</g>
</svg> axis is not drawn to scale and shows various time points and therapy administered. ATG: antithymocyte globulin, R: rituximab, and E: eculizumab.</table>

Case Reports in Hematology

fig3

Figure 3

Figure 3: Response of Paroxysmal Nocturnal Hemoglobinuria Clone with Aplastic Anemia to Rituximab 